疗效和安全性-话题@MedSci

#疗效和安全性#

431篇内容 | 2590人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1721184, encodeId=d9dc1e21184c9, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet Diabetes Endocrinol：达格列净在2型糖尿病年轻患者中的疗效和安全性, objectType=article, longId=724291, objectId=af50e24291eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af50e24291eb, replyNumber=0, likeNumber=82, createdTime=2023-03-27, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af50e24291eb, moduleTitle=Lancet Diabetes Endocrinol：达格列净在2型糖尿病年轻患者中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af50e24291eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721218, encodeId=d93b1e21218f8, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=ESMO 2022：奥布替尼联合R-CHOP治疗既往未经治疗的non-GCB DLBCL患者的疗效和安全性, objectType=article, longId=739080, objectId=9bbfe3908038, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bbfe3908038, replyNumber=0, likeNumber=89, createdTime=2023-03-07, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bbfe3908038, moduleTitle=ESMO 2022：奥布替尼联合R-CHOP治疗既往未经治疗的non-GCB DLBCL患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bbfe3908038)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721115, encodeId=fa701e21115a2, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Immunother Cancer：Nivolumab 联合 ipilimumab治疗晚期罕见妇科肿瘤的疗效和安全性：来自CA209-538临床研究, objectType=article, longId=220657, objectId=8c3622065e52, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c3622065e52, replyNumber=0, likeNumber=104, createdTime=2022-02-09, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c3622065e52, moduleTitle=J Immunother Cancer：Nivolumab 联合 ipilimumab治疗晚期罕见妇科肿瘤的疗效和安全性：来自CA209-538临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c3622065e52)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721216, encodeId=981d1e21216ff, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Eur Acad Dermatol Venereol：Brodalumab治疗中重度斑块状银屑病的长期疗效和安全性 , objectType=article, longId=736658, objectId=f14be366588f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f14be366588f, replyNumber=0, likeNumber=84, createdTime=2023-06-24, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f14be366588f, moduleTitle=J Eur Acad Dermatol Venereol：Brodalumab治疗中重度斑块状银屑病的长期疗效和安全性 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f14be366588f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721129, encodeId=1a2a1e2112939, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Int J Cancer：Pazopanib +FLO (5-FU，奥沙利铂)一线治疗晚期胃癌患者的疗效和安全性：PaFLO研究, objectType=article, longId=221208, objectId=1c1e22120872, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c1e22120872, replyNumber=0, likeNumber=91, createdTime=2022-10-22, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c1e22120872, moduleTitle=Int J Cancer：Pazopanib +FLO (5-FU，奥沙利铂)一线治疗晚期胃癌患者的疗效和安全性：PaFLO研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c1e22120872)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721157, encodeId=6c171e211579d, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Journal of Pain Research：普瑞巴林在治疗中国人群纤维肌痛的疗效和安全性, objectType=article, longId=293662, objectId=12ef2936628b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12ef2936628b, replyNumber=0, likeNumber=66, createdTime=2022-03-01, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12ef2936628b, moduleTitle=Journal of Pain Research：普瑞巴林在治疗中国人群纤维肌痛的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12ef2936628b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721205, encodeId=8b2b1e21205f5, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Clin Oncol：杜瓦鲁单抗联合奥拉帕利治疗初治的转移性尿路上皮癌的疗效和安全性, objectType=article, longId=730446, objectId=7c9fe304466b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c9fe304466b, replyNumber=0, likeNumber=88, createdTime=2022-10-29, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c9fe304466b, moduleTitle=J Clin Oncol：杜瓦鲁单抗联合奥拉帕利治疗初治的转移性尿路上皮癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c9fe304466b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721154, encodeId=c4081e2115450, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Gastric Cancer：III期TAGS研究不同年龄亚组分析Trifluridine and tipiracil (曲氟尿苷替匹嘧啶，FTD/TPI)治疗经治转移性胃/胃食管交界处癌(mGC/GEJC)患者的疗效和安全性, objectType=article, longId=293627, objectId=c7ac29362eb8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7ac29362eb8, replyNumber=0, likeNumber=94, createdTime=2022-10-05, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7ac29362eb8, moduleTitle=Gastric Cancer：III期TAGS研究不同年龄亚组分析Trifluridine and tipiracil (曲氟尿苷替匹嘧啶，FTD/TPI)治疗经治转移性胃/胃食管交界处癌(mGC/GEJC)患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7ac29362eb8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721144, encodeId=7d281e21144ae, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Front Oncol：仑伐替尼（Lenvatinib）单药或联合PD-1抑制剂治疗中国晚期肝癌患者的疗效和安全性, objectType=article, longId=292159, objectId=2e392921592b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e392921592b, replyNumber=0, likeNumber=79, createdTime=2022-10-09, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e392921592b, moduleTitle=Front Oncol：仑伐替尼（Lenvatinib）单药或联合PD-1抑制剂治疗中国晚期肝癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e392921592b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721152, encodeId=64c31e2115271, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Am Acad Dermatol ：组织蛋白酶S抑制剂对中、重度银屑病患者疗效和安全性的研究, objectType=article, longId=293131, objectId=686729313109, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=686729313109, replyNumber=0, likeNumber=80, createdTime=2022-02-10, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=686729313109, moduleTitle=J Am Acad Dermatol ：组织蛋白酶S抑制剂对中、重度银屑病患者疗效和安全性的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=686729313109)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721120, encodeId=f92a1e21120af, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Nat Med： Dalpiciclib（达尔西利）或安慰剂+氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性对比：Ⅲ期DAWNA-1研究, objectType=article, longId=220818, objectId=b1cd22081859, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1cd22081859, replyNumber=0, likeNumber=133, createdTime=2022-10-16, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1cd22081859, moduleTitle=Nat Med： Dalpiciclib（达尔西利）或安慰剂+氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性对比：Ⅲ期DAWNA-1研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1cd22081859)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721219, encodeId=6bdc1e2121997, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）, objectType=article, longId=739082, objectId=0c30e3908258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c30e3908258, replyNumber=0, likeNumber=82, createdTime=2023-07-06, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c30e3908258, moduleTitle=ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c30e3908258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721180, encodeId=83191e211807c, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet Oncol：采用ADC药物Anetumab ravtansine治疗恶性胸膜间皮瘤的疗效和安全性, objectType=article, longId=723522, objectId=d134e23522a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d134e23522a2, replyNumber=0, likeNumber=99, createdTime=2023-01-21, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d134e23522a2, moduleTitle=Lancet Oncol：采用ADC药物Anetumab ravtansine治疗恶性胸膜间皮瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d134e23522a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721095, encodeId=c15f1e210956a, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Dermatolog Treat：Dermalax TM DEEP用于矫正中度至重度鼻唇沟的疗效和安全性, objectType=article, longId=218921, objectId=017b21892120, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=017b21892120, replyNumber=0, likeNumber=81, createdTime=2022-05-24, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=017b21892120, moduleTitle=J Dermatolog Treat：Dermalax TM DEEP用于矫正中度至重度鼻唇沟的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=017b21892120)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721135, encodeId=09bd1e211355d, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Oncologist: Apatinib（阿帕替尼）与S-1联合一线治疗晚期胃癌疗效和安全性, objectType=article, longId=221378, objectId=de1e2213e8db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de1e2213e8db, replyNumber=0, likeNumber=83, createdTime=2022-04-23, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de1e2213e8db, moduleTitle=Oncologist: Apatinib（阿帕替尼）与S-1联合一线治疗晚期胃癌疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de1e2213e8db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721185, encodeId=ce6f1e21185c7, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Thyroid：T3治疗对心脏手术或心血管疾病患者的疗效和安全性分析, objectType=article, longId=724844, objectId=d93fe2484404, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d93fe2484404, replyNumber=0, likeNumber=89, createdTime=2022-11-15, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d93fe2484404, moduleTitle=Thyroid：T3治疗对心脏手术或心血管疾病患者的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d93fe2484404)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721211, encodeId=e5b31e2121181, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Arch Dermatol Res：钙泊三醇-倍他米松复方制剂治疗银屑病的临床疗效和安全性分析, objectType=article, longId=733989, objectId=12c2e339898e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12c2e339898e, replyNumber=0, likeNumber=82, createdTime=2023-01-08, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12c2e339898e, moduleTitle=Arch Dermatol Res：钙泊三醇-倍他米松复方制剂治疗银屑病的临床疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12c2e339898e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721214, encodeId=274d1e212148f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Allergy Asthma Immunol：GSP301鼻腔喷雾剂治疗6-11岁季节过敏性鼻炎儿童的疗效和安全性如何？, objectType=article, longId=735448, objectId=210be354480b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=210be354480b, replyNumber=0, likeNumber=94, createdTime=2023-02-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=210be354480b, moduleTitle=Ann Allergy Asthma Immunol：GSP301鼻腔喷雾剂治疗6-11岁季节过敏性鼻炎儿童的疗效和安全性如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=210be354480b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721195, encodeId=f1731e21195ec, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, objectType=article, longId=727507, objectId=8299e27507ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8299e27507ba, replyNumber=0, likeNumber=90, createdTime=2022-06-11, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8299e27507ba, moduleTitle=JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8299e27507ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721088, encodeId=75941e210889f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Immunother Cancer：免疫检查点抑制剂在伴有牛皮癣患者的疗效和安全性, objectType=article, longId=218548, objectId=8a8921854861, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a8921854861, replyNumber=0, likeNumber=94, createdTime=2022-05-21, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a8921854861, moduleTitle=J Immunother Cancer：免疫检查点抑制剂在伴有牛皮癣患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a8921854861)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

疗效和安全性

2020-05-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet Diabetes Endocrinol：达格列净在2型糖尿病年轻患者中的疗效和安全性

2023-03-27

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

ESMO 2022：奥布替尼联合R-CHOP治疗既往未经治疗的non-GCB DLBCL患者的疗效和安全性

2023-03-07

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Immunother Cancer：Nivolumab 联合 ipilimumab治疗晚期罕见妇科肿瘤的疗效和安全性：来自CA209-538临床研究

2022-02-09

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Eur Acad Dermatol Venereol：Brodalumab治疗中重度斑块状银屑病的长期疗效和安全性

2023-06-24

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Int J Cancer：Pazopanib +FLO (5-FU，奥沙利铂)一线治疗晚期胃癌患者的疗效和安全性：PaFLO研究

2022-10-22

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Journal of Pain Research：普瑞巴林在治疗中国人群纤维肌痛的疗效和安全性

2022-03-01

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Clin Oncol：杜瓦鲁单抗联合奥拉帕利治疗初治的转移性尿路上皮癌的疗效和安全性

2022-10-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Gastric Cancer：III期TAGS研究不同年龄亚组分析Trifluridine and tipiracil (曲氟尿苷替匹嘧啶，FTD/TPI)治疗经治转移性胃/胃食管交界处癌(mGC/GEJC)患者的疗效和安全性

2022-10-05

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Front Oncol：仑伐替尼（Lenvatinib）单药或联合PD-1抑制剂治疗中国晚期肝癌患者的疗效和安全性

2022-10-09

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Am Acad Dermatol ：组织蛋白酶S抑制剂对中、重度银屑病患者疗效和安全性的研究

2022-02-10

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Nat Med： Dalpiciclib（达尔西利）或安慰剂+氟维司群治疗HR+/HER2-晚期乳腺癌的疗效和安全性对比：Ⅲ期DAWNA-1研究

2022-10-16

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

ESMO 2022：阿美替尼辅助治疗可切除的Ⅰ期含实体和／或微乳头成分EGFR敏感突变的非小细胞肺癌的疗效和安全性（APPOINT研究）

2023-07-06

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet Oncol：采用ADC药物Anetumab ravtansine治疗恶性胸膜间皮瘤的疗效和安全性

2023-01-21

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Dermatolog Treat：Dermalax TM DEEP用于矫正中度至重度鼻唇沟的疗效和安全性

2022-05-24

zhaojie88 (审核中...)

前往app查看评论内容

#疗效和安全性#

Oncologist: Apatinib（阿帕替尼）与S-1联合一线治疗晚期胃癌疗效和安全性

2022-04-23

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Thyroid：T3治疗对心脏手术或心血管疾病患者的疗效和安全性分析

2022-11-15

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Arch Dermatol Res：钙泊三醇-倍他米松复方制剂治疗银屑病的临床疗效和安全性分析

2023-01-08

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Allergy Asthma Immunol：GSP301鼻腔喷雾剂治疗6-11岁季节过敏性鼻炎儿童的疗效和安全性如何？

2023-02-19

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

JCO：Durvalumab单独或联合Oleclumab或Monalizumab用于不可切除的III期非小细胞肺癌患者的疗效和安全性：COAST研究

2022-06-11

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Immunother Cancer：免疫检查点抑制剂在伴有牛皮癣患者的疗效和安全性

2022-05-21

科室
- - 订阅+
  - 更多科室
工具
服务